Molecular basis of PD-1 blockade by dostarlimab, the FDA-approved antibody for cancer immunotherapy
Ui Beom Park, Tae Jun Jeong, Nahyeon Gu, Hyun Tae Lee, Yong‐Seok Heo
Topics & Concepts
ImmunotherapyAntibodyCancer immunotherapyMonoclonal antibodyImmunoglobulin light chainChemistryImmune checkpointSteric effectsCancerCancer researchImmune systemStereochemistryMedicineImmunologyInternal medicineCancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCAR-T cell therapy research